



Neuland Q1FY23 income at Rs.221.7 crore

EBITDA at Rs. 29.0 crore

Hyderabad, India, August 3, 2022 - Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the first quarter ended June 30, 2022.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“We had a volatile quarter in which the GDS business saw a decline in revenue as the Prime segment performed below par and impacted EBITDA margins by around 300 bps. However, we witnessed an improved business mix as we saw GDS Specialty revenues from customer launches and pipeline products. We expect the shift in the portfolio to continue and deliver annual performance in line with our plans.”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added *“Although the CMS segment saw delays arising from technical complexities, we see promising growth ahead backed by addition of new projects. Our focus internally is on execution excellence and optimization of costs to ensure mitigation against external events. We remain optimistic that our overall business will grow in line with our long-term plans and reflect higher margins due to our focus on delivering challenging projects in line with our clients’ technical needs.”*

Financial Summary

Rs. crore					
Particulars	Q1FY23	Q4FY22	QoQ Growth (%)	Q1FY22	YoY Growth (%)
Total Income	221.7	256.5	(13.6)%	202.9	9.2%
EBITDA	29.0	39.3	(26.3)%	27.7	4.8%
EBITDA margin (%)	13.1%	15.3%	(220) bps	13.6%	(50) bps
PAT	9.8	21.8	(54.9)%	8.6	13.8%
PAT margin (%)	4.4%	8.5%	(410) bps	4.3%	10 bps
EPS (Basic) Rs.	7.7	17.0	(54.9)%	6.7	13.8%

Q1 FY23 Earnings Call

The company will conduct a one-hour Earnings call at **17:00 hrs. IST on Wednesday, August 3, 2022** where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 38 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 903+ Regulatory filings in the US (60 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Ravi Udeshi, EY IR

Email: ravi.udeshi@in.ey.com